Business Context and Reporting Period
This Form 8-K Current Report was filed by Moderna, Inc. on May 10, 2022. The filing addresses Item 5.02 regarding the departure of a Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
- Severance for Departing CFO: 12 months' salary totaling $700,000 plus 12 months of COBRA coverage.
- Compensation for Returning CFO: Annual salary of $700,000 with an annual incentive target of 90% of base salary.
Material Changes
Executive Leadership Change: Jorge Gomez departed as Chief Financial Officer effective immediately on May 10, 2022. His departure follows an internal investigation disclosed by his former employer, Dentsply Sirona Inc., into matters including financial reporting.
Succession: David Meline, who had recently retired, resumed the role of Chief Financial Officer effective May 11, 2022.
Outlook, Risks, and Unusual Items
Unusual Items and Risks: The filing highlights a reputational and governance risk associated with the departure of Mr. Gomez due to the ongoing investigation at his prior employer. Consequently, Mr. Gomez forfeited his signing bonus, relocation reimbursements, bonus eligibility, and new hire equity awards.
Management Commentary: The Compensation Committee approved specific terms for Mr. Meline's return, including the full vesting of 2022 equity awards that were scheduled for forfeiture upon his retirement and a 12-month extension to exercise vested stock options.
Investor Verification Checklist
- Verify the status and findings of the internal investigation at Dentsply Sirona Inc. involving Jorge Gomez.
- Confirm the effective date of David Meline's return as CFO (May 11, 2022).
- Review the specific terms of the equity vesting extension granted to David Meline.
- Monitor for any future disclosures regarding the impact of the CFO transition on financial reporting processes.
